GlassScriptPhysician profile
Kimberly Leblanc
NPI 1538698857
$5,900.84
in general payments reported to CMS, 2019-2025
39 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $113 · 2021: $262 · 2022: $2,115 · 2023: $917 · 2024: $1,065 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,231 · Long Term Medical Supply Or Device Loan: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.94 |
| Long Term Medical Supply Or Device Loan | $1,180.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,467.19 | 2021-2025 | |
| Illumina, INC. | $1,100.00 | 2022 | |
| Merck Sharp & Dohme LLC | $284.55 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Pfizer INC. | $284.21 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $277.82 | 2022-2023 | Darzalex, Tecvayli, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $256.52 | 2022-2025 | Lynparza, Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $247.67 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Eisai INC. | $227.65 | 2022-2023 | |
| Genentech USA, INC. | $200.82 | 2022-2023 | Tecentriq |
| Janssen Biotech, INC. | $177.92 | 2022-2024 | Tecvayli, Imbruvica, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $158.73 | 2022-2023 | Opdivo, Opdualag |
| Astellas Pharma US INC | $131.38 | 2021-2024 | Padcev |
| Seagen INC. | $127.67 | 2021-2023 | Adcetris |
| Incyte Corporation | $122.76 | 2022-2025 | Monjuvi |
| Amgen INC. | $99.00 | 2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Leblanc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.